Comparison of second-line treatments in metastatic renal cell carcinoma patients: A single-center experience

Renal cell carcinoma is the 10th most common type of cancer, accounting for 3.7% of all cancers. Our study examines patients with metastatic renal cell carcinoma who received Axitinib or Nivolumab as second-line treatment. This study was designed as a retrospective analysis. Patients who received Ax...

Descripción completa

Detalles Bibliográficos
Autores principales: Pehlivan, Metin, Paksoy, Nail, Aydin, Esra, Basaran, Mert, Ekenel, Meltem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578706/
https://www.ncbi.nlm.nih.gov/pubmed/37832108
http://dx.doi.org/10.1097/MD.0000000000035245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578706/
https://www.ncbi.nlm.nih.gov/pubmed/37832108
http://dx.doi.org/10.1097/MD.0000000000035245

Ejemplares similares